Neutraceuticals And India's Swinging Regulatory Pendulum
This article was originally published in Scrip
Executive Summary
A recent recommendation by a sub-committee of India's Drugs Technical Advisory Board (DTAB) classifying a number of popular neutraceuticals as drugs appears to have swung the regulatory pendulum 180 degrees for certain products, leaving some pharma firms in a tizzy.